Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study

The Lancet Neurology

Volumn 11, Issue 2, 2012, Pages 150-156

  Connick, Peter ^a   Kolappan, Madhan ^b   Crawley, Charles ^c   Webber, Daniel J ^a   Patani, Rickie ^a   Michell, Andrew W ^a   Du, Ming Qing ^a   Luan, Shi Lu ^a   Altmann, Daniel R ^d   Thompson, Alan J ^e   Compston, Alastair ^a   Scott, Michael A ^e   Miller, David H ^d   Chandran, Siddharthan ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CLINICAL ARTICLE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; OPTIC NERVE; PRIORITY JOURNAL; RASH; UNITED KINGDOM; VISUAL ACUITY; VISUAL SYSTEM;

ADULT; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 84856023693     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70305-2     Document Type: Article

References (33)

1. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006, 13:700-722.
2. Compston A, Coles A Multiple sclerosis. Lancet 2008, 372:1502-1517.
3. Coles AJ, Compston DAS, Selmaj KW, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
4. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
5. Coles A The curious incident of disability in multiple sclerosis trials. Lancet Neurol 2006, 5:899-900.
6. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
7. Arthur A, Zannettino A, Gronthos S The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol 2009, 218:237-245.
8. Uccelli A, Laroni A, Freedman MS Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011, 10:649-656.
9. Payne N, Siatskas C, Barnard A, Bernard CCA The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis. Curr Stem Cell Res Ther 2011, 6:50-62.
10. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
11. Zhang J, Li Y, Lu M, et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res 2006, 84:587-595.
12. Bai L, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57:1192-1203.
13. Gerdoni E, Gallo B, Casazza S, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007, 61:219-227.
14. Kassis I, Grigoriadis N, Gowda-Kurkalli B, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008, 65:753-761.
15. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
16. Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27:1421-1432.
17. Carrion F, Nova E, Ruiz C, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010, 19:317-322.
18. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007, 4:50-57.
19. Yamout B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 2010, 227:185-189.
20. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67:1187-1194.
21. Mehta LR, Schwid SR, Arnold DL, et al. Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler 2009, 15:542-546.
22. Kolappan M, Henderson APD, Jenkins TM, et al. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009, 256:305-319.
23. Connick P, Kolappan M, Patani R, et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 2011, 12:62.
24. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
25. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
26. Johnson NA, Hamoudi RA, Ichimura K, et al. Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest 2006, 86:968-978.
27. Oberg AL, Mahoney DW Linear mixed effects models. Methods Mol Biol 2007, 404:213-234.
28. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
29. Barkhof F, Bruck W, De Groot CJA, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003, 60:1073-1081.
30. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004, 56:407-415.
31. Franklin RJM, Ffrench-Constant C Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008, 9:839-855.
32. Rivera FJ, Couillard-Despres S, Pedre X, et al. Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells 2006, 24:2209-2219.
33. Bai L, Caplan A, Lennon D, Miller RH Human mesenchymal stem cells signals regulate neural stem cell fate. Neurochem Res 2007, 32:353-362.